• On August 20, 2026, Medtronic’s board approved a second-quarter fiscal 2027 cash dividend of US$0.72 per share, payable October 16 to shareholders of record on September 25, reinforcing its 49-year streak of annual dividend increases and status in the S&P 500 Dividend Aristocrats index.
• This dividend affirmation, alongside expectations for broad-based growth in Medtronic’s upcoming fiscal first-quarter 2027 results and ongoing innovation in areas like digital health and Neuroscience, highlights how income stability and product progress are shaping investor expectations for the company.
• Now we’ll examine how the reaffirmed dividend and anticipated broad-based earnings growth alter Medtronic’s existing investment narrative and risk balance.

AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Medtronic Investment Narrative Recap

To own Medtronic, you generally need to believe its diversified device portfolio and long dividend record can offset execution risks in underperforming units and new product ramps. The latest dividend affirmation is more a confirmation of that income thesis than a change in the story, while the near term catalyst remains whether upcoming earnings validate expectations for broad-based segment growth. The biggest current risk is that margin and revenue recovery in weaker businesses takes longer than hoped.

The most relevant recent announcement here is the expected fiscal first quarter 2027 earnings, where analysts are looking for around US$9.47 billion of revenue with growth across Cardiovascular, Neuroscience, Medical Surgical and Diabetes. How those results line up with the reaffirmed dividend will likely shape whether investors continue to see Medtronic as simply a stable payer or as a company that is also regaining operating momentum in its core growth platforms.

Yet despite the reassuring dividend, investors should still understand the legal and earnings risks that could pressure Medtronic if...

Medtronic's narrative projects $41.5 billion revenue and $6.6 billion earnings by 2029. This requires 4.5% yearly revenue growth and a $1.8 billion earnings increase from $4.8 billion today.

Uncover how Medtronic's forecasts yield a $98.00 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were assuming only about 2 percent annual revenue growth and earnings of roughly US$6.2 billion by 2029, so compared with the broad based growth and EP ecosystem potential many focus on, their narrative is much more cautious and could easily shift again once this dividend decision and upcoming results are fully absorbed.

Explore 9 other fair value estimates on Medtronic - why the stock might be worth as much as 29% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Medtronic research is our analysis highlighting 5 key rewards that could impact your investment decision.
• Our free Medtronic research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Medtronic's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.
• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.